(3.235.236.13) 您好!臺灣時間:2021/05/15 03:55
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:廖俊正
研究生(外文):Chun-Cheng
論文名稱:社區老年人代謝症候群相關因素調查研究
論文名稱(外文):Metabolic Syndrome and its Related Factors Among the Elderly in a Community
指導教授:李孟智李孟智引用關係
學位類別:碩士
校院名稱:中山醫學大學
系所名稱:醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2010
畢業學年度:98
語文別:中文
論文頁數:82
相關次數:
  • 被引用被引用:3
  • 點閱點閱:146
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
前言:代謝症候群是一群與心臟血管疾病相關的危險因子結合,不但會導致糖尿病或心血管疾病的罹病率上升,也會增加全死因之死亡率。目前台灣六十五歲以上老年人的數目也已超過總人口數的10%以上,而此階段族群更是代謝症候群高危險群。而現在國內針對六十五歲以上的老年人代謝症候群的研究雖然慢慢在重視,但針對台中基層里民至今尚未有具代表性的相關研究。
目的:基於上述原因,來探討台中某地區六十五歲以上老年人代謝症候群之盛行率與其相關因素調查,並分析(一)、以國民健康局2007年公告實施修正代謝症候群診斷標準來看此族群的代謝症候群盛行率。(二)、以身體質量指數分三層其代謝症候群的盛行率各為何。(三)、以身體質量指數、急性發炎指標、總膽固醇、低密度膽固醇與總膽固醇與高密度膽固醇之比值等在老年人代謝症候群與非代謝症候群是否有相關性。(四)、用ㄧ些與心血管相關因子來看是否能預測老年人的代謝症候群,並探究其關連性。
方法:本論文為橫斷式研究,主要為台中某地區六十五歲(含)以上里民代謝症候調查(轄下共39里),統計的資料共1051筆(男性為589筆、女性為462筆資料)。研究中的常態分佈之統計以百分比或平均值±標準差來表示,非常態分佈則是用中位數(IQR)來呈現。而對於連續性變項的比較則採用 Student’s t test 之統計方法來分析,若為非常態變項則用無母數的Mann-Whitney U test來分析。最後使用邏輯斯回歸分析檢定一些與心血管疾病相關的因子,看這些因子是否有預測代謝症候群的能力,而所有統計分析的檢定均以 p < 0.05 當做統計上有意義的參考。
結果:發現此年齡層代謝症候群的盛行率高達約48.1%,比國內外文獻研究都還高。若以身體質量指數分組之分析發現,BMI越大,代謝症候群盛行率就越高,而在六十五歲以上的老年人更是明顯。研究也發現由身體質量指數、總膽固醇與高密度膽固醇比值、CRP、總膽固醇、和低密度膽固醇等五個自變項所建立的邏輯式迴歸模型,對於此族群代謝症候群預測正確率是非常之高。
結論:本研究顯示台中某地區六十五歲以上老年人代謝症候群之盛行率非常高,政府應更加重視此問題對於老年族群健康危害,並將高密度脂蛋白膽固醇優先列入民眾成人健康檢查必檢項目,以早期診斷出代謝症候群。



Introduction: Previous studies indicate that metabolic syndrome (MetS), which represents a combination of risk determinants, has recently been acknowledged as a risk factor for cardiovascular disease, type 2 diabetes mellitus, and hypertension. It is also associated with mortality. Nowadays the number of the group that are greater than 65 years old have exceeded 10% of the number of the general populations. We also know that this group is at the high risk of developing MetS. Although the government have put emphasis on the studies of MetS for those who are greater than 65 years old, no representative studies have yet been conducted in Taichung community
Objectives: Base on above reasons, we will analyze the contributing factors for the prevalence rate of the metabolic syndrome and its related factors among the elderly in a community. This study targets four topics: (1) The prevalence rate of metabolic syndrome among the elderly greater than 65 years old based on 2007 modified MetS Taiwan criteria; (2) The prevalence rate of metabolic syndrome among the groups which were divided by BMI; (3) The relation or difference between MetS group and non-MetS group; (4) Whether some cardiovascular risks would influence MetS or not.
Method: This is a cross-sectional study which involves 1,051
individuals (589 males and 462 females) from a Taichung community (39 units in this community). Data was expressed as the mean with standard deviation and median with inter-quarter range for continuous variables. Student’s t test and Mann-Whitney U test for unpaired data were used for the comparison of mean and median values between metabolic syndrome group and non- metabolic syndrome group. Logistic regression was used for examing the risk factors which are associated with cardiovascular diseases, so as to predict MetS. The goodness of fit in model was also examined.
Results: The prevalence rate of metabolic syndrome in our study was 48.1%. The number of the female patients who suffered from metabolic syndrome was higher than that of the male ones. This figure presented in this result was obviously higher than the studies done overseas or in our country. CRP was significantly different between the metabolic syndrome group and non- metabolic syndrome group. Logistic regression showed that BMI, total cholesterol, low density lipoprotein cholesterol and total-to-HDL cholesterol ratio have strong a relationship with metabolic syndrome.
Conclusion: The prevalence rate of metabolic syndrome is relatively higher among the elderly. So the government should put more emphasis on this problem. To conclude, the examination on the high density of lipoprotein cholesterol should be added to the elders’ health check-up items in order to diagnose the problem sooner.


目錄
致謝…… ………………………………………………………………… i
中文摘要 …………………………………………………….……...…… iii
英文摘要 …………………………………………………………....…… v
目錄 ………………………………………………………….…………... viii
表目錄 …………………………………………………………...………. x
圖目錄 ……………………………………………………………………. xii
第一章 緒論. …………………………………………………...……... 1
第一節 研究背景與研究動機 …………………………………...…... 1
第二節 研究目的.. ………………………………………...…...…...... 3
第二章 文獻探討 ………………………………………………...…... 5
第一節 代謝症候群的 發展史……………………...…....……...…… 5
第二節 代謝症候 群的診斷標準……………………………………... 6
第三節 代謝症候群的流行病學… ………………………………….. 11
第四節 代謝症候致病機轉…................................ ………………….. 16
第五節 血中總膽固醇與高密度脂蛋白膽固醇比值及C-反應蛋白
的觀念…………19
第六節 與代謝症候群有關的併發症…………… ………………… 20
第三章 研究方法….. ……………………………………………...…. 28
第一節 研究架構 ………………………………………………...…... 28
第二節 研究對象…………… …………………………………...…... 30
第三節 衡量內容……… ……………………………..………….…... 30
第四節 研究變項之診斷標準.. ……………………………………… 32
第五節 資料統計分析………… ……………………………...…….. 33
第四章 研究結果 …………………………………………...………... 34
第五章 討論 ……………………………………………...…………... 40
第六章 結論與建議 …………………………………………...……. 50
第一節 結論….......... ………………………………………………… 50
第二節 未來建議…... ………………………………………………… 52
第七章 研究限制……... ………………………………………………… 54
參考文獻………………. ………………………………………………… 55



1.中華民國內政部統計處:內政統計月報:戶籍登記現住人口數按五歲、十歲年齡組分。2010/06/17取自http:// sowf. moi.gov.tw/ stat/ month/list.htm
2.Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87(1):4-14, 2010.
3.Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 26(1):13-24, 2007.
4.行政院衛生署: 97年度死因統計, 2009。
5.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 365(9468):1415-28, 2005.
6.Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 28(4):629-36, 2008.
7.Balkau B, Valensi P, Eschwege E, Slama G. A review of the metabolic syndrome. Diabetes Metab. 33(6):405-13, 2007.
8.Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 92(2):399-404, 2007.
9.Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 27(10):2444-9, 2004.
10.Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 105(8):626-35, 2006.
11.Wen CJ, Lee YS, Lin WY, Huang HL, Yao CA, Sung PK, et al.The metabolic syndrome increases cardiovascular mortality in Taiwanese elderly. Eur J Clin Invest. 38(7):469-75, 2008.
12. 張明毅、林鉅勝、唐憶淨:某榮民安養機構老年男性代謝症候群之盛行率及其與死亡率的關係。臺灣老年醫學暨老年學雜誌 4(2): 130-42, 2009。
13.Lai SW, Liao KF, Li TC, Lin HF, Lin WY, Lin CH. Metabolic syndrome in older people in Taiwan: a hospital-based study. Intern Med J. 36(10):648-51, 2006.
14.行政院衛生署國民健康局:成人(20 歲以上)代謝症候群之判定標準, 2007。
15.Studien KE. Hypertonsion-Hyperglycamie-hyperuricemia syndrome. Zentralblatt fuer Innere Medizin 44:105-27, 1923.
16.Haller H. [Epidermiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med. 32(8):124-8, 1977.
17.Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37(12):1595-607, 1988.
18.Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 149(7):1514-20, 1989.
19.Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 41(6):715-22, 1992.
20.Hayden MR, Tyagi SC. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 1:3, 2002.
21.Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15(7):539-53, 1998.
22.Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 16(5):442-3, 1999.
23.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285(19):2486-97, 2001.
24.Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 9(3):237-52, 2003.
25.International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 1st International Congress on Prediabetes and the Metabolic Syndrome in Berlin, Germany. 2005.
26.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112(17): 2735-52, 2005.
27.黃麗卿、黃國晉:代謝症候群的定義與流行病學。臺灣醫學 11(4): 363-9, 2007。
28.行政院衛生署國民健康局:代謝症候群定義及其臨床診斷準則, 2004。
29.Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287(3):356-9, 2002.
30.Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 26(3): 575-81, 2003.
31.莊紹源、陳震寰、蔡世澤、周碧瑟、潘文涵:Clinical Identification of the Metabolic Syndrome in Kinmen。中華民國心臟學會雜誌 18(1):16-26, 2002。
32.Guh JY, Chuang LY, Chen HC. Betel-quid use is associated with the risk of the metabolic syndrome in adults. Am J Clin Nutr. 83(6): 1313-20, 2006.
33.張昌堯、郭雅音、陳佑寧、洪錦墩、陳榕生、廖朝財:南投地區中老年人代謝症候群盛行率。生檢雜誌20: 40-6, 2009。
34.Ravaglia G, Forti P, Maioli F, Bastagli L, Chiappelli M, Montesi F, et al. Metabolic Syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care. 29(11):2471-6, 2006.
35.Gause-Nilsson I, Gherman S, Kumar Dey D, Kennerfalk A, Steen B. Prevalence of metabolic syndrome in an elderly Swedish population. Acta Diabetol. 43(4):120-6, 2006.
36.Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic Syndrome and Mortality in Older Adults: The Cardiovascular Health Study. Arch Intern Med. 168(9):969-78, 2008.
37.Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 444(7121):881-7, 2006.
38.Reaven GM. The insulin resistance syndrome. Curr Atheroscler 5(5): 364-71, 2003.
39.Reaven GM. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 1(1):9-14, 2005.
40.Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 116(7):1813-22, 2006.
41.Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 47(6): 1093-100, 2006.
42.Wang TD, Chen WJ, Chien KL, Seh-Yi Su SS, Hsu HC, Chen MF, et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol. 88(7): 737-43, 2001.
43.Holman RR, Coleman RL, Shine BS, Stevens RJ. Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. Diabetes Care. 28(7):1796-7, 2005.
44.Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 27(8): 1991-7, 2004.
45.Lee IT, Huang CN, Lee WJ, Lee HS, Sheu WH. High total-to-HDL cholesterol ratio predicting deterioration of ankle brachial index in Asian type 2 diabetic subjects. Diabetes Res Clin Pract. 79(3):419-26, 2008.
46.Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 286(3):327-34, 2001.
47.Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 33(2):351-75, 2004.
48.Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288(21): 2709-16, 2002.
49.Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 49(4):403-14, 2007.
50.Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Metabolic syndrome as a risk factor for coronary heart disease and stroke: an 11-year prospective cohort in Taiwan community. Atherosclerosis. 194(1):214-21, 2007.
51.Shattock SG. A Report upon the Pathological Condition of the Aorta of King Menephtah, traditionally regarded as the Pharaoh of the Exodus. Proc R Soc Med. 2(Pathol Sect):122-7, 1909.
52.Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 138(5 Pt 2):S419-20, 1999.
53. 蘇大成:膽固醇與心血管健康。台大醫網 35-6, 2003。
54.Insull W, Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 122(1 Suppl): S3-S14, 2009.
55.Sattar N, Gaw A, Scherbakova O, Ford I, O''Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 108(4):414-9, 2003.
56.Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 231(1):25-30, 1992.
57.Zavaroni I, Mazza S, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, et al. High plasma insulin and triglyceride concentrations and blood pressure in offspring of people with impaired glucose tolerance. Diabet Med. 7(6):494-8, 1990.
58.Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 20(9):2140-7, 2000.
59.Mykkanen L, Haffner SM, Rainwater DL, Karhapaa P, Miettinen H, Laakso M. Relationship of LDL size to insulin sensitivity in normoglycemic men. Arterioscler Thromb Vasc Biol. 17(7): 1447-53, 1997.
60.Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 92(1):141-6, 1993.
61.Wilson PW, D''Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 112(20):3066-72, 2005.
62.Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 366(9491):1059-62, 2005.
63.Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients'' risk. Obes Res. 6 (Suppl 1):8S-17S, 1998.
64.Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 163(4):427-36, 2003.
65.Holst-Schumacher I, Nunez-Rivas H, Monge-Rojas R, Barrantes-Santamaria M. Components of the metabolic syndrome among a sample of overweight and obese Costa Rican schoolchildren. Food Nutr Bull. 30(2):161-70, 2009.
66.王培寧、李明濱:代謝症候群與失智症。台灣醫界雜誌52(12): 11-3, 2009。
67.Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology. 67(5):843-7, 2006.
68.Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol. 66(3):324-8, 2009.
69.Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 45(10):1831-8, 2009.
70.Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 107(1):28-36, 2006.
71.Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 164(8):769-74, 2006.
72.行政院衛生署:成人健康體位挑戰1824, 2004。
73.Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 5(4):377-83, 2002.
74.Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care. 24(10):1758-63, 2001.
75.Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet. 60(1):143-52, 1997.
76.Li HJ, Huang CY, Lee HC, Chen MR, Lo FS, Lin CH, et al. Insulin resistance in obese adolescents. Acta Paediatr Taiwan. 46(2):61-6, 2005.
77.Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. All-cause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care. 30(9): 2381-7, 2007.
78.Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 351(25):2599-610, 2004.
79.Rutter MK, Meigs JB, Sullivan LM, D''Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 110(4):380-5, 2004.
80.Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 25(11):2016-21, 2002.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top